Mergers and acquisitions in the life sciences sector

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Mergers and acquisitions in the life sciences sector
  • Drivers of M&A activity
  • Executing life sciences M&A deals
  • Due diligence
  • Product due diligence
  • Product-focused approach
  • Product life cycle
  • IP due diligence considerations
  • IP rights
  • Specific IP due diligence considerations
  • More...

Mergers and acquisitions in the life sciences sector

On 31 January 2020, the UK ceased to be an EU Member State and entered an implementation period during which it continues to be treated by the EU as a Member State for many purposes. As a third country, the UK can no longer participate in the EU’s political institutions, agencies, offices, bodies (except to the limited extent agreed), but it continues to be subject to EU law and must submit to the continuing jurisdiction of the Court of Justice of the EU in accordance with the transitional arrangements in Part 4 of the Withdrawal Agreement. For further reading, see: Brexit—Life Sciences and News Analysis: Brexit Bulletin—key updates, research tips and resources.

In recent years, the life sciences sector has experienced significant merger and acquisition (M&A) activity. This Practice Note discusses some of the factors that have driven deal flow in the industry and explores some of the key considerations legal counsel should be mindful of when representing parties to such transactions. For the purposes of this Practice Note, the life sciences sector is generally considered to include pharmaceuticals, health-oriented biotechnology products and medical devices. This Practice Note focuses on issues that are common in life sciences M&A transactions and issues that tend to assume more importance in life sciences deals than in deals in other industries. Industry-specific

Popular documents